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Abstract The late Na current is of pathophysiological im-
portance for the heart. Ranolazine is an innovative anti-
ischemic and antianginal agent that inhibits the late Na
current, thereby reducing the Na-dependent Ca-overload,
which improves diastolic tone and oxygen handling during
myocardial ischemia. In addition, ranolazine seems to exert
beneficial effects on diastolic cardiac function. Moreover,
there are experimental and clinical data about its antiarrhyth-
mic properties. A beneficial atrial selectivity of ranolazine
has been suggested that may be helpful for the treatment of
atrial fibrillation. The purpose of this review article is to
discuss possible future clinical indications based on novel
experimental and preclinical results and the significance of
the available data.
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Introduction: The Late Na Current
Under physiological conditions, sarcolemmal Na channels
open transiently and are quickly inactivated, thereby pro-
ducing the peak Na current (INa) and, thus, the upstroke of
the action potential. In addition, a late component of INa was
described due to Na channels that remain active, inactivate
with much slower kinetics, or reopen. The amplitude of this
current is small with about 1 % of the amplitude of peak INa,
but it may persist for hundreds of milliseconds. Because late
INa can be elevated up to about 5 times under pathological
conditions [1], one can imagine that the integral of this
persistent current may exceed the one of peak INa leading
to Na accumulation in the myocyte. It is known that intra-
cellular Na concentration frequency dependently can in-
crease by several mM [2]. In human heart failure,
intracellular Na concentration can be up to 6–8 mM higher
as compared to nonfailing myocardium [3].
Different Na channel isoforms are known (eg, Nav1.1–
Nav1.8), with the pore-forming subunit Nav1.5 being the
cardiac specific isoform. The contribution of Na channel
isoforms for late INa and its modulation by different patho-
logical conditions are not fully understood. Most of the
studies identified Nav1.5 as the late INa producing channel
[4]. Auxiliary ß subunits also exist [5]. There is one report
that shows that neuronal isoforms Nav1.1 and Nav1.6 in-
crease proportionally with increasing late INa in pressure-
overloaded rat hearts [6]. Also, mutations in the Na channel
gene SCN5A encoding for Nav1.5 that are associated with
the long QT syndrome 3 produce slowed inactivation there-
by increasing late INa [7].
Of broader clinical relevance are acquired disease states
such as ischemia, myocardial infarction, and heart failure
that are known to be associated with an elevated late INa
[8–10]. We have shown that late INa is increased in myo-
cytes from patients with atrial fibrillation (AF) [11••] and in
isolated myocardium from patients with heart failure and
diastolic dysfunction [12].
As mentioned above, an elevated late INa is considered to
be a potent contributor of Na overload [12, 13]. Although
Na overload itself cannot activate myofilaments directly,
increasing Na levels can lead to Ca overload through the
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Na/Ca-exchanger (NCX). Normally, the NCX exchanges
one Ca ion for three Na ions per cycle. However, the NCX
can work in two different directions. In its forward mode, it
eliminates Ca out of the cell to accomplish diastolic relax-
ation (in addition to sarcoplasmic reticulum Ca reuptake
mainly through the sarcoplasmic reticulum Ca ATPase). In
its reverse mode (usually during the action potential pla-
teau), it transports Ca into the cell in exchange to trans-
sarcolemmal elimination of Na. The activity and direction of
the transport depends on the membrane potential and, thus,
on the action potential as well as the intracellular Na and Ca
concentration (ie, the electrochemical gradient). Na accu-
mulation and prolonged action potential duration occur dur-
ing myocardial hypoxia and promote reverse mode of the
NCX [14]. The consequence is an impaired overall capacity
of the cell to eliminate Ca from the cytosol leading to
intracellular Ca overload. This leads to or aggravates dia-
stolic dysfunction due to increased myofilaments activation
[15]. Thus, diastolic activation of contractile proteins caus-
ing increased wall tension prolonging extravascular com-
pression of intramural vessels reduces oxygen supply [16].
Additionally, elevated diastolic tone increases energy con-
sumption and aggravates disturbed energy balance like a
vicious cycle [17].
Inhibition of Late INa
Ranolazine is an inhibitor of late INa and is available for
clinical purposes since 2006 as an anti-ischemic agent
(Ranexa® [Gilead Sciences, Inc., Foster City, CA]) [18,
19]. In cardiac myocytes from dogs and guinea pigs, rano-
lazine was shown to cause a concentration-, voltage-, and
frequency-dependent inhibition of late INa [20]. Inhibitory
effects of ranolazine on late INa were demonstrated in mul-
ticellular myocardium and in isolated cardiac myocytes [12,
21, 22]. Although ranolazine also has some peak INa inhib-
iting effects, it has an up to 38-fold higher potency for late
INa as compared to peak INa with a half maximal inhibitory
concentration (IC50) of 6.5 versus 244 μM [21] in ventricular
myocytes with a therapeutic range of 2–8 μM. Regarding the
binding site of ranolazine on the cardiac Na channel, two
independent studies described mutation of a single amino acid
residue, F1760A and F1759K, in the putative local anesthetic
binding site of the cardiac Na channel Nav1.5 [7], and the
skeletal muscle channel Nav1.4 [23], showing that this mu-
tation reduced the late INa inhibiting effects of ranolazine.
However, it remains unclear how ranolazine produces its
selective effect on late INa.
Interestingly, in two very recent studies, additional modes
of action of ranolazine were suggested. Beyder et al. [24•]
could show a mechanosensitivity of Nav1.5 in isolated car-
diac myocytes and that ranolazine was able to reduce this
novel activation mechanism. However, this effect seemed to
be independent of the suspected binding site F1760. There-
fore, the exact molecular mode of action remains unex-
plained. Of not, a stretch-dependent effect on intracellular
Na handling was previously proposed by us mainly through
reverse mode NCX [25]. In addition, Lovelock et al. [26]
could describe an effect of ranolazine on myofilament Ca
sensitivity, thereby improving diastolic function.
Late INa Inhibition in Heart Failure: Effects on Cytosolic
Na and Ca Handling
Diastolic heart failure is characterized by signs and symp-
toms of heart failure. These patients show a decreased
compliance and relaxation of the ventricles and present with
preserved ejection fraction (HFpEF). Unfortunately, there
are no evidence-based agents for treating HFpEF. Because
late INa is elevated in human heart failure [10], there is
ongoing effort to investigate possible effects of ranolazine
in conditions of heart failure.
Almost 20 years ago, there was an elegant in vivo study
showing an improved diastolic function in noninfarcted
ischemic hearts in a small number of patients before and
in the presence of intravenous application of ranolazine
[27]. Moreover, acute infusion of ranolazine in patients with
long QT syndrome 3 with increased late INa caused a sig-
nificant improvement of diastolic relaxation in parallel to an
abbreviation of the QT time [28].
In addition, a recent echocardiographic study investigat-
ed the effects of ranolazine in patients with stable angina
with preserved ejection fraction [29••]. After 2 months de-
celeration time E, isovolumic contraction time, and isovo-
lumic relaxation time decreased, whereas ejection time
increased. Global left ventricular function also improved,
as indicated by a decrease in the myocardial performance
index.
Interestingly, a subgroup analysis of the Metabolic Effi-
ciency with Ranolazine for Less Ischemia in Non-ST Eleva-
tion Acute Coronary Syndromes (MERLIN TIMI-36) study
revealed that patients with an acute coronary syndrome and
elevated B-type natriuretic peptide levels (> 80 pg/mL), and
thus increased wall stress, were at significantly higher risk of
the primary trial end point of cardiovascular death and myo-
cardial infarction at 1 year [30].
In contrast to the small number of clinical trials, there are
a couple of experimental studies using ranolazine in vivo
and in vitro in different heart failure models. First, in dogs
with heart failure, acute infusion of ranolazine significantly
reduced left ventricular end diastolic pressure, and increased
ejection fraction as well as stroke volume [31]. Most impor-
tantly, these effects were observed in the absence of signif-
icant changes in heart rate or blood pressure. In another
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study, ranolazine was investigated as a chronic treatment
option in a heart failure model again in dogs [32]. This study
additionally examined the effects of ranolazine treatment in
combination with the ß-blocker metoprolol or the
angiotensin-converting enzyme (ACE) inhibitor enalapril.
Ranolazine was capable to significantly prevent progressive
left ventricular dysfunction as well as global and cellular
myocardial remodeling.
Our group investigated isolated trabeculae from human
end-stage failing hearts that exhibited frequency-dependent
diastolic dysfunction in vitro [12]. Addition of ranolazine
did not cause negative inotropy but significantly ameliorat-
ed disturbed intracellular ion handling and reduced the
increase in diastolic tension (ie, improved diastolic dysfunc-
tion [Fig. 1]). Interestingly, those trabeculae with severe
diastolic dysfunction benefit from late INa inhibition even
more. This hypothesis could be confirmed in experiments in
isolated rabbit myocytes that were exposed to anemone
toxin (ATX-II) to mimic increased late INa in heart failure.
Using fluorescent dyes, the increase in cytosolic Na was
paralleled by elevated intracellular diastolic Ca levels. Treat-
ment with ranolazine significantly attenuated the effects of
ATX-II leading to markedly reduced diastolic Ca levels in
addition to lowering Na levels. Interestingly, ranolazine
secondarily accelerated the NCX forward mode activity
measured by analysis of Ca transients decay during caffeine
applications [12]. This increase in NCX forward mode dis-
plays the link between ranolazine-modulated cytosolic Na
and Ca in such a way that both stimuli of the reverse NCX
mode in heart failure, elevated [Na]i and prolonged action
potential duration, become attenuated by exposure to rano-
lazine, leading to improved Ca elimination during diastole.
The results of this in vitro study led us to initiate the
Ranolazine in Diastolic Heart Failure (RALI-DHF) trial
(NCT01163734) to investigate intravenous ranolazine appli-
cation in vivo followed by 2 weeks oral treatment in patients
with diastolic dysfunction due to severe HFpEF in a small
proof-of-concept placebo-controlled study (Fig. 2) [33].
Interestingly, isolated papillary muscles from transgenic
mice overexpressing Ca/calmodulin-dependent protein ki-
nase II (CaMKII), which is known to be upregulated in
heart failure [34] and to induce late INa, had frequency-
dependent diastolic dysfunction [35]. Addition of ranolazine
markedly improved diastolic tension under basal conditions
but to a greater extent under frequency-induced stress, sug-
gesting that CaMKII may be activated by increased Ca
levels (and hence Ca overload) thereby activating late INa
(Fig. 2). Indeed, direct effects of CaMKII on Na channels
(and thus late INa) were described previously [36] and
underlined by computational modeling [37] and even effects
of reactive oxygen species on late INa were recently shown
to be mediated by CaMKII [38].
Our findings are consistent with earlier studies in animals
showing that ranolazine attenuates diastolic dysfunction in
the hearts of rabbit and rat models during ischemia/reperfu-
sion [39, 40], in the presence of ischemic metabolites [41] or
reactive oxygen species [42], and in dogs with experimen-
tally induced heart failure [22]. In summary, most of the
experimental studies performing acute exposure to ranola-
zine in heart failure report on positive effects on diastolic
performance. This is different to a long-term study in heart
failure dogs where both improved diastolic parameters and
ejection fraction were described [31].
Late INa Inhibition for the Treatment of Arrhythmias
Late INa is expected to influence electrophysiological cell
properties in addition to cytosolic Na handling. Thus, it is
Fig. 1 Original traces representing diastolic dysfunction in heart fail-
ure and improvement upon ranolazine (Adapted from Sossalla et al.
[12].)
Fig. 2 Schematic diagram showing the design of the RALI-DHF
study. RALI-DHF Ranolazine in Diastolic Heart Failure; NYHA New
York Heart Association class; EF ejection fraction; LVEDP left ven-
tricular end diastolic pressure; NT-proBNP N-terminal pro–B-type
natriuretic peptide; ECG electrocardiogram; Echo echocardiogram;
CPET cardiopulmonary exercise testing; Pat patient; i.v. intravenous;
PCWP pulmonary capillary wedge pressure; PAP pulmonary artery
pressure; SVR systemic vascular resistance; PVR pulmonary vascular
resistance; dP/dt; rate of pressure change in the ventricle
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not surprising that ranolazine has been shown to have beneficial
effects on arrhythmias in vitro and in vivo. In general, ranola-
zine exerts antiarrhythmic capacities very likely via inhibition
of late INa, but also peak INa and rapid delayed rectifier potas-
sium current IKr under certain circumstances. While inhibition
of late INa is the principal electrophysiological effect of ranola-
zine in ventricular myocardium, the inhibition of peak INa
seems to be of great importance in atrial myocardium.
A pathophysiologically increased late INa by itself can
alter cellular electrophysiology by two distinguished ways
and thus increase the propensity for arrhythmias, i.e. i)
elevation of late INa which prolongs cardiac action poten-
tials, and ii) elevation of late INa which causes cellular Na-
dependent Ca overload and thus the electrogenic transient
inward current ITi.
Early afterdepolarizations are more likely to occur during
a prolonged action potential duration, which can be induced
by enhancing late INa. Moreover, transmural differences of
late INa, and hence action potential duration, might increase
transmural dispersion of repolarization and QT interval,
which underlies the development of torsade de pointes
arrhythmias [20].
In contrast, Ca overload, which occurs when late INa is
elevated [12], and leakiness of the cardiac ryanodine recep-
tor are believed to participate as crucial events in the initi-
ation and propagation of spontaneous sarcoplasmic
reticulum Ca release events and/or proarrhythmogenic Ca
waves [43]. The consequence may be elimination of cyto-
solic Ca via the NCX, which generates ITi, which can give
rise to delayed afterdepolarizations [44]. Song and cow-
orkers [45] have shown the crucial importance of late INa
for arrhythmias in guinea pig atrial myocytes. They ob-
served early and delayed afterdepolarizations as well as
triggered activity. Also, elevation of late INa induced a Ca-
dependent ITi. All effects could be abolished by ranolazine
or tetrodotoxin. Moreover, Ca chelating agents, Na/Ca-ex-
change blockers, and the sarcoplasmic reticulum Ca release
inhibitor ryanodine could prevent delayed afterdepolariza-
tions and triggered activity. Because early afterdepolariza-
tions could not be prevented using these agents, it is
suggested that action potential prolongation causes early
afterdepolarizations in a Ca-independent manner.
First results of antiarrhythmic properties of ranolazine
were reported in a guinea pig in vitro model of long-QT
syndrome 3 [46] and in the presence of ATX-II [47], a
selective inducer for late INa. In these studies, ranolazine
reduced both afterdepolarizations as arrhythmic triggers and
the transmural and temporal dispersion of repolarization as
an arrhythmic substrate. Therefore, the efficacy of ranola-
zine was potentially ascribed to its late INa-blocking proper-
ties. Further studies underlined the antiarrhythmic effects of
ranolazine; intact rat hearts subjected to ischemia/reperfu-
sion showed a reduced incidence and duration of ventricular
arrhythmias upon ranolazine treatment [48]. Recently, rano-
lazine had efficacy against both pacing-induced re-entrant
and multifocal ventricular fibrillation in isolated-perfused
rat hearts with H2O2-mediated early afterdepolarizations
and triggered activity [49•].
Moreover, ranolazine reversed abnormalities of repolari-
zation (prolonged action potential duration, beat-to-beat
variability, and dispersion of action potential duration and
early afterdepolarizations) of ventricular myocytes from
failing canine hearts [22]. Also, it was shown recently that
atrial myocytes from mice with long QT 3 mutation with
increased late INa show greatly increased action potential
duration and early afterdepolarizations, and ranolazine re-
duced action potential duration [50••].
However, ranolazine also inhibits IKr in cardiac myocytes
[20]. Blocking IKr causes prolongation of the ventricular
action potential. Therefore, the net effect of ranolazine on
the action potential is mainly driven by the relative magni-
tude of reductions in late INa (inward) and IKr (outward)
currents during the repolarization period.
It should be noted that there are also reports showing
antiarrhythmic effects of ranolazine under conditions with-
out elevated late INa. Antzelevitch et al. [20] revealed potent
effects of ranolazine to suppress early afterdepolarizations in
myocytes isolated from the middle of the left ventricular
wall and Purkinje fiber preparations. Midmyocardial cells
are known to have action potentials that prolong dispropor-
tionately relative compared to those of epi- or endocardial
cell types in response to many QT-prolonging drugs [51,
52]. Moreover, these cells have the largest late INa while IKr is
similar in all three cell types. Accordingly, ranolazine produ-
ces a preferential abbreviation of midmyocardial cell action
potential duration, leading to a reduction in transmural disper-
sion of repolarization [20]. In contrast to other IKr blockers
such as sotalol, extrasystolic activity and spontaneous torsade
de pointes arrhythmias were never observed in this study.
Their findings are in agreement with a report from an anes-
thetized dog model with chronic complete atrioventricular
block in which ranolazine-attenuated torsade de pointes epi-
sodes induced by IKr blockers [53] and studies involving
isolated guinea pig and rabbit hearts [46, 54].
Late INa Inhibition for the Treatment of Atrial
Fibrillation
Rhythm control remains important in the treatment of AF,
but cannot be effectively achieved without the risk of po-
tential side effects such as proarrhythmia, hypotension, or
sometimes organ toxicity with current drugs (eg, dronedar-
one or amiodarone), except for ß-blockers. Thus, there is a
demand for novel pharmacological strategies to treat AF.
Ranolazine has potent effects on atrial arrhythmias (eg, AF)
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that are worth mentioning. In the MERLIN TIMI-36 trial a
significant reduction of supraventricular tachycardias was
observed in patients that were treated with ranolazine. Al-
though a low incidence of AF was found, patients treated
with ranolazine were less likely to have a new onset of AF.
While 75 patients developed new AF in the placebo group,
only 55 individuals had new-onset AF during treatment
with ranolazine. However, this trial was not designed and
statistically powered to investigate new onset of AF. Never-
theless, in addition to this remarkable finding during assess-
ment of ranolazine’s safety, further studies are warranted.
Murdock et al. [55] investigated high-dose ranolazine as
a pill in the pocket approach. They found that 72 % of the
patients with paroxysmal AF converted to sinus rhythm
after application of 2,000 mg of ranolazine (single dose).
Although very promising, the limitation of this study is that
no placebo collective was included. In another pilot project,
ranolazine was helpful in maintaining sinus rhythm in
patients with resistant AF in whom more established meas-
ures had failed [56].
Finally, there is preliminary evidence from a recent ab-
stract that investigated the effects of ranolazine compared to
amiodarone to prevent AF following bypass surgery [57]. In
this retrospective trial, baseline characteristics such as age,
important other diseases, drug pretreatment, and others were
not statistical different between both groups. Ranolazine
(generally 1,500 mg preoperatively followed by 1,000 mg
twice daily for 10 days) was given to 111 patients and 145
patients were treated with amiodarone (generally 400 mg
preoperatively followed by 200 mg twice daily for 10 days).
Patients treated with ranolazine were significantly less likely
to experience AF, with an incidence of 15 % compared to
26 % in patients treated with amiodarone. Although the
result of this retrospective trial is promising, selection bias
cannot be ruled out as a cause for the reduced incidence of
AF with ranolazine. So far, clinical data seems to be prom-
ising but it is limited due to trial design and number of
patients.
One major problem concerning Na channel blockers in
the past is the fact that they can cause ventricular proar-
rhythmia as it was demonstrated in the Cardiac Arrhythmia
Suppression Trial (CAST) trial [58]. Hence, atrial selective
peak INa inhibition would be an attractive approach for the
treatment of atrial rhythm disorders due to the lack of
ventricular proarrhythmia. It has been reported that ranola-
zine acts as an atrial selective peak INa inhibitor [59] but it
selectively inhibits late INa in ventricular myocytes [20].
While it remains unclear how ranolazine selectively inhibits
late INa in ventricular myocytes, its capacity to inhibit peak
INa in atrial myocytes was largely attributed to electrophys-
iological differences between atrial and ventricular myocar-
dium [59]. In the latter report the authors have properly
announced some atrial capacities that may account for the
atrial selective profile (inhibition of peak INa) of ranolazine
which was formerly described as an inactivated state blocker
[22]: i) the half inactivation voltage is 16 mV more negative
in atrial compared to ventricular myocytes; and ii) a more
depolarized resting membrane potential in atrial cells that is
generally accepted.
Although ranolazine was described to act as an inacti-
vated state blocker, recent studies suggest that it preferen-
tially binds rather to open versus inactivated Na channels,
staying trapped in the channel during inactivation and un-
binding during resting state [23, 60]. During rapid recovery
from inhibition at the resting state, inhibition of peak INa
might be atrial selective independent of open or inactivated
blocking properties of the agent. This might be explained by
a smaller fraction of rested Na channels at resting membrane
potential in atrial compared to ventricular myocytes.
Accordingly, we also have shown that ranolazine inhibits
peak INa in human atrial myocytes [11••]. We further found
that inhibition of Na channels by ranolazine was frequency
dependent, such as the higher the frequency the higher the
inhibition rate. Faster activation rates are associated with
abolished diastolic intervals, and the slow repolarization of
the action potential phase 3 causes a slower unbinding of
ranolazine from the channel. This phenomenon causes ac-
cumulation of block at fast, but not at slow frequencies. This
might be explained by the capacity of ranolazine to disso-
ciate rapidly from the resting state of the Na channel and
may be of therapeutic importance during high atrial frequen-
cies as it is known for AF.
Because Burashnikov et al. investigated myocytes with-
out electrical remodeling (but this usually occurs during
AF), these data are limited to conditions where electrical
remodeling has not taken place yet [59]. Therefore, we
additionally investigated atrial myocytes from patients with
chronic AF and showed significantly reduced peak INa den-
sity (~16 %) in AF versus sinus rhythm, which was accom-
panied by a 26 % lower expression of Nav1.5 while
neuronal Na channel isoforms were upregulated [11••]. In
contrast, late INa was significantly increased in myocytes
from AF atria by about 26 %. In a second step we exposed
myocytes to ranolazine and found a marked reduction of late
INa by about 60 % in myocytes from patients with AF but
only by about 18 % in myocytes from patients with sinus
rhythm. Although late INa integral per beat decreases with
increasing frequencies, the high frequency (and thus an
increasing late INa integral per minute) during AF might
largely counteract this effect, leading to Na-dependent Ca
overload Thus, it is likely that these effects of ranolazine
independent of the action potential duration are important in
human AF where Ca overload is also present [61].
But what may be the net effect of ranolazine on action
potential duration in patients with AF with shortened action
potential duration (as usually shown in AF)? Although there
Curr Heart Fail Rep (2012) 9:183–191 187
is competition between effects of ranolazine on late INa and
IKr, which also determines action potential duration, we
have observed that ranolazine rather prolongs action poten-
tial in human atrial myocytes (Maier L, unpublished). Fur-
thermore, it was shown that ranolazine does not shorten but
rather prolongs action potential duration in dog atrial myo-
cytes [59]. This may have been due to the fact that ranola-
zine also inhibits IKr. Inhibition of IKr would counteract this
phenomenon leading to prolonged atrial refractoriness. In-
deed, it was previously shown that ranolazine prolongs atrial
action potential duration, which leads to elimination of
diastolic intervals and a more depolarized takeoff potential
at rapid rates [59]. This effect may further potentiate the
atrial selectivity for peak INa inhibition and possibly the
clinical effectiveness of ranolazine. Taken together, inhibi-
tion of late INa via ranolazine may possess beneficial effects
on cellular Na-dependent Ca overload similar to its property
to block peak INa and IKr, which are accepted strategies for
the treatment of AF.
Moreover, Kumar et al. [62] investigated atrial electrical
properties of ranolazine in an intact porcine heart. They
found that ranolazine increased atrial effective refractory
period and prolonged conduction time in a frequency-
dependent manner. These effects were more pronounced in
the atria than in ventricle, as was also observed previously
[59]. Intravenous application of ranolazine also decreased
acetylcholine-induced AF duration, the dominant frequency
of the arrhythmia, and tended to suppress reinduction of AF
in a porcine model [63]. The same group further provided
evidence that intrapericardial ranolazine exhibits striking
atrial antiarrhythmic actions in the intact porcine heart
[64]. This was evidenced by increases in refractoriness and
here in AF inducibility.
Recently, Sicouri et al. [65] investigated possible syner-
gistic effects of ranolazine in combination with chronic
amiodarone on AF. Their data indicate that the combination
of both agents produced an atrial-selective inhibition of Na
channel parameters and prevented induct ion of
acetylcholine-induced AF, that was much greater than treat-
ment alone, and greater than the algebraic sum of the indi-
vidual treatments. Therefore, this study points to a
synergism of the effects of the two therapies. Regarding
severe organ toxicity, which is regular produced by amio-
darone, it is of special interest that dronedarone in combi-
nation with low doses of ranolazine similarly resulted in
atrial-selective depression of sodium channel–dependent
parameters and effective suppression of AF [66••].
It also has been shown that ranolazine exerts antiarrhyth-
mic action in canine pulmonary vein sleeve preparations,
where this agent caused a frequency-dependent inhibition of
Na channel activity leading to post-repolarization refracto-
riness, conduction slowing, and suppression of triggered
activity [67].
Finally, we do not know which AF patient might benefit
most from ranolazine, and thus, there is a huge need for
clinical studies to investigate the effects of ranolazine on
persistent and paroxysmal AF. Therefore, two placebo-
controlled studies were recently initiated, including the Rano-
lazine in Atrial Fibrillation Following An Electrical Cardio-
version (RAFFAELLO) trial investigating ranolazine in
patients with persistent AF after electric cardioversion and
how efficient sinus rhythm can be maintained over a period
of 4 months (www.ClinicalTrials.gov; NCT01534962). The
HARMONY trial investigates a combination of ranolazine
and low-dose dronedarone in patients with paroxysmal AF
assess ing AF burden (www.Cl in ica lTr i a l s .gov:
NCT01522651) [68].
Conclusions
In summary, there are increasingly experimental and pre-
clinical data for a beneficial role of ranolazine in diastolic
dysfunction and cardiac arrhythmias in addition to its cur-
rent antianginal role. We believe that further experimental
studies and future clinical trials will shed light onto the
potential impact and future indications for ranolazine to treat
patients possibly with certain arrhythmias, forms of heart
failure most likely with diastolic dysfunction and HFpEF.
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